GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

* CONVELO THERAPEUTICS ENTERS INTO COLLABORATION AND OPTION TO ACQUIRE AGREEMENT WITH GENENTECH TO DISCOVER NOVEL REMYELINATING THERAPIES

The following Spanish stocks may be affected by newspaper reports and other factors on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

* SAID ON MONDAY ITS UNIT INSTITUT UNIV. DE CIENCIA TECNOLOGIA SA (IUCT) HAD FILED FOR INSOLVENCY PROCEEDINGS SINCE IT WAS NOT POSSIBLE TO REACH AN AGREEMENT WITH CREDITORS WITHIN TIME LIMITS OF PRE-INSOLVENCY PROCEDURE

* Gilead makes $3.95 bln upfront payment, $1.1 equity investment

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Monday:

* Study meets main goal of improvement in progression free survival

GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.